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Using an electrochemical platform based
on DNA charge transport, Furst and
Barton show that DNMT1, the most
abundant human methyltransferase, is
more active in colorectal tumor tissue.
DNMT1 hyperactivity does not correlate
with either overexpression or total
amount of DNMT1, and might be a
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DNMT1, the most abundant human methyltransfer-
ase, is responsible for translating the correct methyl-
ation pattern during DNA replication, and aberrant
methylation by DNMT1 has been linked to tumorigen-
esis. We have developed a sensitive signal-on elec-
trochemical assay for the measurement of DNMT1
activity in crude tissue lysates. We have further
analyzed ten tumor setsandhave foundadirect corre-
lation between DNMT1 hyperactivity and tumorous
tissue. In the majority of samples analyzed, the
tumorous tissuehas significantly higherDNMT1activ-
ity than the healthy adjacent tissue. No such cor-
relation is observed in measurements of DNMT1
expression by qPCR, DNMT1 protein abundance by
western blotting, or DNMT1 activity using a radio-
metric DNA labeling assay. DNMT1 hyperactivity can
result from both protein overexpression and enzyme
hyperactivity.DNMT1activitymeasuredelectrochem-
ically provides a direct measure of activity in cell ly-
sates and, as a result, provides a sensitive and early
indication of cancerous transformation.
INTRODUCTION
Colorectal cancer is the third most prevalent cancer worldwide,
causing approximately 700,000 mortalities annually (Forman
et al., 2013). The study of the causes of this disease is especially
important, as its diagnosis is on the rise among people under the
age of 50, and one of the major causes of mortality from this dis-
ease is metastasis due to its late detection (Mandelblatt et al.,
1996). Many molecular factors have been found to contribute
to the onset of this disease, including a host of genetic mutations
(Fearon and Vogelstein, 1990; Lengauer et al., 1997; Liu et al.,
1995; Vogelstein and Kinzler, 2004) and epigenetic modifications
(Jones and Laird, 1999; Feinberg and Tycko, 2004; Jones and
Baylin, 2002; Frigola et al., 2006), as well as the inactivation of
DNA repair pathways (Leach et al., 1993; Lynch and de la Chap-
elle, 2003; Jin and Robertson, 2012).
While many factors likely contribute to the initiation and devel-
opment of colorectal cancer, epigenetic modifications are of
special interest, as they are connected to the progression of a938 Chemistry & Biology 22, 938–945, July 23, 2015 ª2015 Elsevier Lvariety of cancers (Sharma et al., 2010; Esteller, 2008). DNA
methylation in particular has garnered significant interest, as
aberrant DNA methylation has been found to be a hallmark of
many cancers (Baylin and Herman, 2000; Esteller, 2007),
including colorectal cancer (Toyota et al., 1999a, 1999b).
Genomic hypermethylation is often found in colorectal cancer
and has been linked to the methylation of tumor suppressor
genes and genes for DNA repair proteins, leading to their
silencing and, therefore, tumorigenesis (Esteller et al., 2001;
Fearon and Vogelstein, 1990; Esteller et al., 2000).
In humans, there are two classes of methyltransferases: de
novo methyltransferases (DNMT3a, DNMT3b, and DNMT3L)
and maintenance methyltransferases (DNMT1). De novo meth-
yltransferases are in relatively low copy number and are res-
ponsible for establishing methylation patterns on the genome,
meaning that they have a large preference for unmodified
DNA (Okano et al., 1999). In contrast, DNMT1, the most
abundant mammalian methyltransferase, is a maintenance
methyltransferase responsible for transferring the genomic
methylation pattern from the parent DNA strand to the daughter
strand during DNA replication (Bestor, 2000). Because of its
vital role in maintaining genomic methylation patterns during
DNA replication, DNMT1 may be important in these molecular
transformations that lead to the development of colorectal
cancer.
Despite the potential importance of DNMT1 activity in disease
initiation and progression, there is currently no clinical test for its
activity. Generally, qPCR, which can be used to quantify gene
expression of this protein, is used as a correlative measurement
for the total amount of DNMT1 present (El-Deiry et al., 1991).
Other methods, such as bisulfite sequencing (Toyota et al.,
1999a, 1999b; Zou et al., 2002), are used to detect specific, dis-
ease-relevant methylation patterns for early clinical diagnosis.
However, such techniques are very costly and have limited effi-
cacy (Munteanu andMastalier, 2014). To obtain a direct measure
of methyltransferase activity, the current laboratory gold stan-
dard involves radiolabeling DNA with a tritium-labeled methyl
group (Fraga and Esteller, 2002). This assay not only produces
relatively high variability but also requires the use of radioactivity
and specialized instrumentation for measurement, making it
impractical for clinical use.
We have previously developed an electrochemical method for
the assessment of DNMT1 activity from crude cultured cell and
tissue lysate (Furst et al., 2014). This assay is conducted on a
multiplexed platform with two working electrodes (Figure 1)
that enables electrochemical readout from disperse DNAtd All rights reserved
Figure 1. Electrochemical Array for Detection of DNMT1 Activity
The array contains two sets of 15 gold electrodes, each embedded in a Teflon
plate. Each electrode has a diameter of 1 mm. The two complementary Teflon
arrays are assembled with a 150-mm spacer between them, which was pre-
viously determined to be the optimal distance such that signals are not diffu-
sion limited (Furst et al., 2014). The electrodes of the primary (bottom) array are
modified with DNA of the desired sequences such that DNA-mediated charge
transport is detectable. The electrodes of the secondary (top) array are bare for
electrochemical detection.monolayers with signal amplification and no necessary back-
ground correction. With this platform, low-density DNA mono-
layers are formed through electrochemical activation of an inert
copper precatalyst into an active catalyst (Furst et al., 2013).
Electrochemical readout is accomplished through the measure-
ment of current generated from a catalytic cycle. In this cycle,
DNA-mediated charge transport reduces an intercalative redox
probe, methylene blue, to leucomethylene blue. This form of
the probe has a reduced affinity for DNA, destacking from the he-
lix and entering solution. In solution, leucomethylene blue re-
duces the ferricyanide electron sink to ferrocyanide, in turn
becoming reoxidized to methylene blue. Amplified DNA-medi-
ated electrochemical signals are generated without necessi-
tating background correction through the detection of the
current generated from the reoxidation of ferrocyanide at the
secondary electrode array, which is proportional to the amount
of ferrocyanide present (Figure 2). This cycling enables signifi-
cant signal amplification, leading to very sensitive detection.
Using this sensitive detection platform, the methylation state of
DNA can be assayed easily. Bound to the electrode is a hemi-
methylated oligonucleotide duplex. Methylation of this DNA
substrate is converted into an electrochemical signal through
treatment of the hemi-methylated DNA bound to the electrode
with a methylation-specific restriction enzyme; if the DNA oligo-
nucleotide on the electrode has been fully methylated by
DNMT1, restriction is inhibited and the electrochemical signal re-
mains large. On the other hand, if the DNA is not further methyl-
ated by DNMT1, the restriction enzyme cuts the DNA, and the
signal, reflecting the amount of DNA, is significantly diminished
(Figure 2) (Muren and Barton, 2013). Thus the assay is rapid, re-
quires no background correction or complex instrumentation,
and requires only 500 mg of tissue per electrode, which is signif-Chemistry & Biology 22,icantly less sample than is currently required with a biopsy (Furst
et al., 2014).
Using this platform, we evaluate DNMT1 activity in ten sets of
tumor tissue and healthy adjacent tissue, as well as in cultured
colorectal carcinoma and normal colon cells. Significantly
more DNMT1 activity is observed electrochemically in themajor-
ity of the tumor samples compared with their healthy tissue
counterparts, making this assay promising as an early clinical
diagnostic for cancerous transformations.
RESULTS
DNMT1 Activity Measured Electrochemically
The electrochemical assay for DNMT1 activity involves the signal-
on detection of methylation events on synthetic substrate DNA
tethered to an electrode surface (Muren and Barton, 2013). The
process involves two steps: first, the pure methyltransferase or
crude lysate is added to the surface. Subsequently, a methyl-
ation-specific restriction enzyme is used to cut any DNA that
was not methylated during the previous treatment step. Success-
ful methylation, resulting in protection from amethylation-specific
restriction enzyme,maintains an electrochemical signal (Figure 2),
while inactivity of themethyltransferase on the DNA-modified sur-
face results in a significantly diminished electrochemical signal
following treatment with a restriction enzyme.
When pure DNMT1 is titrated onto a DNA-modified electrode
modified with hemi-methylated DNA, a binding curve is gener-
ated, and a binding constant can be extracted based on the
percentage of the electrochemical signal that remains following
restriction of the substrate DNA. A similar binding curve is gener-
ated from the addition of pure DNMT1 to the lysate of 4,000
HCT116 DNMT1/ cultured cells (the previously determined
optimal lysate concentration for DNMT1 activity detection) (Furst
et al., 2014). The titration data, along with the curve fit to the Hill
binding model, are shown in Figure 3. Based on the inflection
point of this curve, a KD of pure DNMT1 on this DNA-modified
electrode is found to be 31 ± 1.3 nM, and 32 ± 1.8 nM for pure
DNMT1 in HCT116 DNMT1/ lysate. These values are in good
agreement with previously determined values for the KD of
DNMT1 in solution (26 nM) (Lee et al., 2005). A surface KD on
the same order as solution values indicates that not only is our
platform especially sensitive for the detection of this protein
but also that the morphology of the DNA on our surface mimics
the native substrate for the DNMT1 protein, allowing full access
of the protein to the DNA bound to the surface.
Similarly, the differential signal protection from tumor and
adjacent healthy tissue sets can bemeasured electrochemically.
Ten tumor sets (A–J), which were received snap-frozen with no
further treatment, were evaluated, and an example (tissue set
A) is shown in Figure 3. Electrochemical data for this set show
significant DNMT1 hyperactivity in the tumor sample compared
with the normal adjacent tissue over several replicates. With
the data shown, an electrochemical assay using pure, isolated
DNMT1 (green bar in Figure 3) is always included as a positive
control. It should also be noted that both the tumor lysate and
adjacent healthy tissue lysate are tested for methyltransferase
activity using a hemi-methylated and an unmethylated DNA
substrate. It is clear, even without normalization to the healthy
adjacent tissue, that tumor A has significantly more DNMT1938–945, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 939
Figure 2. Signal-On Electrochemical Assay
for DNMT1 Detection
(Left) The bottom electrode modified with a dilute
DNA monolayer is responsible for generating
electrochemical signals through DNA-mediated
charge transport (CT) amplified by electrocatalysis.
Methylene blue (MB+), a DNA intercalating redox
probe, is reduced by DNA CT to leucomethylene
blue (LB+), where it can interact with an electron
sink, ferricyanide. Upon interaction, ferricyanide
is reduced to ferrocyanide, reoxidizing leuco-
methylene blue to methylene blue in the process.
Current is generated and detected at the second-
ary electrode from the reoxidation of ferrocyanide.
The current generated is proportional to the
amount of ferrocyanide oxidized, which depends
on the amount of methylene blue reduced by DNA
CT to LB+ and dissociated. To detect DNMT1,
crude lysate (multicolored shapes in background)
is added to the electrode. If DNMT1 (blue heart) is
capable of methylating the hemi-methylated DNA
substrate (green arrows), the DNA on the electrode
becomes fully methylated. If the protein is not
active, the DNA remains hemi-methylated (red arrows). The lysate is washed away prior to the addition of the restriction enzyme. Amethylation-specific restriction
enzyme (BssHII, brown heart) is then added that cuts the hemi-methylated DNA (red arrow), decreasing the amount of bound methylene blue and significantly
attenuating the electrochemical signal, while leaving the fully methylated DNA untouched. (Right) Constant potential amperometry is used tomeasure the percent
change before and after restriction enzyme treatment. If the restriction enzyme did not affect the DNA (top), the signals overlay. If, however, the restriction enzyme
cuts the DNA, the signal is significantly attenuated (bottom). Constant potential amperometry is run for 90 s with a 320-mV potential applied to the secondary
electrode and a400-mV potential applied to the primary electrode relative to an AgCl/Ag reference. All scans are in Tris buffer (10 mMTris, 100mMKCl, 2.5 mM
MgCl2, 1 mM CaCl2 [pH 7.6]) with 4 mM methylene blue and 300 mM potassium ferricyanide.activity than the healthy tissue. In addition, the incorporation of a
comparison between the hemi-methylated and unmethylated
substrates ensures that the activity we monitor is specific to
DNMT1 and not to any de novo methyltransferases, given the
noted preference of DNMT1 for a hemi-methylated substrate
(Hermann et al., 2004).
The data for each tissue set tested (A–J) have been aggre-
gated into a single graph indicating the fold excess of DNMT1
activity in the tumor tissue compared with the normal adjacent
tissue (Figure 4). To calculate fold excess, each tumor and
adjacent normal tissue have been normalized for the signal pro-
tection for the unmethylated DNA substrate to account for
methylation that is not DNMT1 specific. Subsequently, the tumor
tissue value is normalized to the adjacent healthy tissue, produc-
ing a ratio. If the fold excess is >1, the DNMT1 activity in the
tumor is higher than in the adjacent tissue. A fold excess of <1
indicates lower activity in the tumor relative to the healthy tissue,
while a value of 1 indicates equivalent expression. As can be
seen in Figure 4, none of the tumors exhibits lower DNMT1 activ-
ity than their healthy tissue counterparts. In fact, the vastmajority
of the samples show significantly higher activity of DNMT1
compared with the healthy tissue.
Radiometric Assay for DNMT1 Activity
In addition to measuring DNMT1 activity with our electrochemical
assay, the current generally used radiochemical assay for DNMT1
activity (Fraga and Esteller, 2002) was used to assess the ten
tumor samples. This assay involves the addition of substrate
DNA and tritium-labeled S-adenosylmethionine (SAM) cofactor,
the source of methyl groups, to crude lysate or pure DNMT1. Pro-
tein activity is extrapolated from the amount of radioactivemethyl-940 Chemistry & Biology 22, 938–945, July 23, 2015 ª2015 Elsevier Lation added to the DNA following incubation, determined through
scintillation counting of the samples in triplicate. Just as with the
electrochemical assay, both hemi-methylated and unmethylated
substrate DNA were tested with the crude lysate for methylation.
Analogously to the electrochemical assay, the resulting fold
excess is calculated based on the ratio of hemi-methylated sub-
strate to unmethylated substrate counts for the tumor sample
normalized to the hemi-methylated divided by the unmethylated
counts for the normal tissue. As can be seen in Figure 4, although
the trend in fold excess activity is similar for tritium labeling as for
electrochemistry, the extent of hyperactivity is diminished across
all samples. In addition, the majority of the samples have essen-
tially statistically equivalent activity measured in this manner.
This is, in part, due to the correction for the activity on unmethy-
lated DNA. In this assay, genomic DNA from the lysate remains
in the reaction mixture and is therefore capable of being methyl-
ated and contributing to the overall activity, even though it is not
the target substrate. This seems to have led to higher activity in
theunmethylatedsubstrate samples for the tumors inmanycases,
which, when corrected, may lead to overall lower fold excess ac-
tivity. The values that simply compare the hemi-methylated tumor
counts with their normal tissue counterparts are shown in Figures
S1andS2.Becauseof this largedifference, tritium labelingofDNA
appears to be less precise than electrochemicalmeasurements of
specific DNMT1 activity from lysate.
DNMT1 Expression Measured by RT-qPCR
At present, the most common method to analyze methyltrans-
ferases from lysate is through evaluation of genomic expression
of the methyltransferase of interest. Thus, as a baseline with
which to compare our electrochemical data, the expression oftd All rights reserved
Figure 3. Detection of DNMT1 in Pure Form
and from Crude Lysate
A titration of pure DNMT1 protein (left) demon-
strates the sensitivity of this method of detection.
In blue is shown the titration of pure DNMT1 on our
electrodes, while in red is shown pure DNMT1
added to HCT116 DNMT1/ cultured cell lysate.
When the data are fit to a Hill binding model (fits
shown as solid traces in plot), a KD of 31 ± 1.3 nM
protein is extracted for pure DNMT1 and 32 nM ±
1.8 nM for DNMT1 added to lysate. The data from
an array used to measure the DNMT1 activity from
tumor A (right) show the differential between active
lysate on electrodes and inactive lysate. The green
bar shows electrodes treated with 65 nM pure
DNMT1 as a positive control. The blue bars show electrodes treated with tumor A lysate on hemi-methylated substrate (solid) and unmethylated substrate
(dashed). The red bars show electrodes treated with adjacent normal tissue A lysate on hemi-methylated DNA (solid) and unmethylated DNA (dashed). As can be
seen, a significantly higher amount of signal protection is observed for the tumor tissue on the hemi-methylated substrate than for the adjacent normal tissue on
that substrate. The error bars show SE across three electrodes.the DNMT1 gene in each tumor and adjacent healthy tissue sam-
ple was evaluated by RT-qPCR. A relative quantification method
was used to determine the fold excess of DNMT1 gene expres-
sion in the tumor sample compared with the adjacent normal tis-
sue sample. For each set of samples, the relative abundance of
DNMT1 is first normalized to the expression of b-actin in each
sample, followed by comparison between the normal tissue and
tumor tissue. A fold excess of DNMT1 from each tumor and
normal tissue pair is calculated: a value of >1 indicates higher
expression in the tumor in comparison with the normal tissue,
<1 indicates lower expression in the tumor compared with the
healthy tissue, and a value of 1 indicates equivalent expression.
Multiple primer sets were evaluated for consistency over multi-
ple trials, and themost consistent resultswere obtainedwithReal-
TimePrimers,whichwere used for bothDNMT1 andb-actinquan-
tification by RT-qPCR. As can be seen in Figure 5, there is a large
degree of variability among the ten tumor sets regarding the over-
expression of DNMT1 in the tumors compared with the normal
adjacent tissues. Sample B has the most significant upregulation,
with a 22 ± 5 fold excess of DNMT1 expression, while sample G
has significant downregulation of DNMT1 in the tumor sample,
with a fold excess of 0.3 ± 0.1. Overall, no trends were observed
with regard to theexpressionofDNMT1among these samples; tu-
morsA,B,E, andF, aswell as theHCT116cells comparedwith the
CCD-18Co cells, all have significant upregulation ofDNMT1 in the
tumor tissue. SamplesC,D, and I haveequivalentDNMT1 expres-
sion compared with adjacent tissue, while samples G, H, and J
have significant downregulation of DNMT1 in the tumors.
Protein Content Measured by Western Blot
In addition to DNMT1 expression evaluated by RT-qPCR, the to-
tal DNMT1 protein content of each tissue sample was evaluated
by western blotting. Total nuclear protein (60 mg) was added to
each lane, and the amount of DNMT1 protein in the tumor tissue
compared with the healthy adjacent tissue was determined
through quantification of the bands resulting from the western
blot (Figure 5). Again, a large degree of variability is observed
in the total amount of DNMT1 within each lysate sample. The
bands for DNMT1 protein as well as the nuclear protein Lamin
A, used as a loading control, are given in Figure S3. Importantly,
compared with the normal adjacent tissue, the ratio of DNMT1 inChemistry & Biology 22,the tumor correlates directly with the fold excess of the DNMT1
gene expression quantified by RT-qPCR.
Figure 6 compares our electrochemical measurement of
activity for the various tumor samples, normalized to the adja-
cent healthy tissue, with DNMT1 expression, also normalized.
Remarkably, as is evident in Figure 6, there is no correlation
between expression levels and resultant activity. While, for
example, sample D has comparable expression levels in the
tumor and adjacent tissue, the protein is found to be hyperactive
electrochemically. In the case of sample B, the high activity seen
electrochemically appears instead to be a function of the very
high expression levels. Thus the electrochemical measurements
allow a clear determination of methyltransferase activity associ-
ated with a given sample, and comparisons with expression and/
or western blotting permit the evaluation of whether the high
activity in a given tumor sample results from high protein content
or protein hyperactivity. The electrochemical assay is seen to
provide the most direct measure of DNMT1 activity, not simply
its cellular abundance.
DISCUSSION
The electrochemical platform developed for the measurement
of DNMT1 activity allows the detection of this protein from
crude cultured cell and colorectal tissue lysates. However,
the utility of this platform for potential clinical diagnostic applica-
tions rests in the analysis of many samples. Here, ten tumor
samples and adjacent healthy tissue have been evaluated.
Our electrochemical platform facilitates extremely sensitive pro-
tein detection, with femtomole detection limits for the DNMT1
protein (Furst et al., 2014). Furthermore, the electrochemical
assay is a signal-on method of detection, ensuring specific
DNMT1 discrimination from a host of proteins, DNA, and RNA
fragments found in crude lysates. Importantly, measurements
of methyltransferase activity using the hemi-methylated versus
unmethylated substrate distinguishes the methyltransferase
activity as associated with DNMT1 from that in other methyl-
transferases, since only DNMT1 is preferentially active on the
hemi-methylated substrate (Hermann et al., 2004).
From the electrochemical analysis of the ten samples tested,
in addition to lysate from cultured colorectal carcinoma cells, a938–945, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 941
Figure 4. DNMT1 ActivityMeasured Electro-
chemically and Radioactively
The fold excess activity measured electrochemi-
cally (left) shows hyperactivity (fold excess >1) in all
but two of the tissue samples. Those that do not
show hyperactivity show equivalent DNMT1 ac-
tivity between tumor and normal tissue (fold
excess 1). When DNMT1 activity is measured
with radioactive labeling (right), the same hyper-
activity is not observed, likely because the mea-
surement is convoluted by genomic DNA in the
lysate samples. In both cases, the data for both the
tumor and normal tissue on the hemi-methylated
substrate are first normalized to that of the un-
methylated substrate, and the data for the tumor
tissue are then normalized to the normal adjacent
tissue. Data for hemi-methylated substrates
without normalization to unmethylated substrates are shown in Figures S1 and S2. Error bars represent the standard error for three trials. Each of the letters
represents one of the tumor and healthy adjacent tissue sets, and the bar denoted ‘‘Cells’’ represents the result from the comparison between HCT116 colorectal
carcinoma and healthy CCD-18Co cultured cells.pattern was found to emerge. Hyperactivity in the tumor samples
in comparison with the normal tissue is clearly found in the ma-
jority of tissue specimens analyzed. Furthermore, the few sam-
ples that did not show hyperactivity in the tumor tissue have
equal activity between the tumor and healthy tissue. In fact, we
performed a one-way ANOVA between the tumor and normal
adjacent tissue DNMT1 activity. Despite our small sample size
(10), we found a confidence level of p < 0.05, indicating a 95%
confidence that the DNMT1 activity in the tumor tissues is
different from the healthy adjacent tissues.
At present, the most prevalent method of methyltransferase
activity measurement is a radioactivity assay involving the appli-
cation of tritium-labeled SAM cofactor to the methyltransferase
of interest in pure form or in a mixture from crude lysate (Furst
et al., 2014). Substrate DNA is added to the reaction, and activity
is measured based on scintillation counts resulting from tritium-
labeled methyl groups added to DNA. This assay is also used
here as a comparison with our electrochemical assay. The re-
sults from this activity assay, however, show less hyperactivity
in the tumor samples than in the electrochemical assay. Indeed,
the radioactivity assay does not show for most samples a statis-
tically clear hyperactivity of DNMT1 in tumorous tissue. This
lack of a clear correlation is likely due to methylation of genomic
DNA present in the lysate, which is inseparable from measure-
ments of the methylation of the synthetic, target DNA added to
the reaction. Tritium labeling, therefore, does not provide a
pure measurement of DNMT1 activity on a target substrate
when measured from lysate, as methylation of native DNA can
affect the levels ofmethylationmeasured and, therefore, the ratio
of methylation on hemi-methylated versus unmethylated sub-
strates. It is especially important to note that this is not a problem
with our electrochemical assay, as the only DNA methylation
events that contribute to the electrochemical signal are those
that occur on the target DNA in the electrochemical device.
Noteworthy also is that the tritium-based assay is not suitable
for clinical applications, due to the large amounts of reagents
required and the necessity of radioactivity for detection.
Perhaps more important in the context of clinical relevance
is the comparison of DNMT1 activity measurements with the
primary method currently applied in analysis of clinical sam-942 Chemistry & Biology 22, 938–945, July 23, 2015 ª2015 Elsevier Lples: gene expression of the DNMT1 gene by RT-qPCR. Many
studies have focused on correlations between the expression of
this methyltransferase gene and tumorigenesis (El-Deiry et al.,
1991; De Marzo et al., 1999; Peng et al., 2005; Girault et al.,
2003). However, upon analysis of the ten sample sets involved
in this study, no such correlation is observed. There are just as
many samples that have upregulation of DNMT1 in tumors as
have equivalent expression and underexpression. We also
observe no correlation between the activity of DNMT1 in a sample
and its gene expression level as measured by RT-qPCR. Thus,
while RT-qPCR has potential applications for general research
regarding methyltransferases, in and of itself, it is insufficient as
a diagnostic to identify potentially tumorous transformations.
Western blotting for total DNMT1 protein content in the lysate
samples yields results similar to those of RT-qPCR. The DNMT1
protein levels are found to correlate to the expression ofDNMT1,
but not to the activity of the protein measured electrochemically.
This finding indicates that it is not simply the amount of protein
present that is responsible for the hyperactivity in the tumor sam-
ples observed electrochemically. Electrochemical measurement
of DNMT1 activity is not a measure of the total amount of
DNMT1, but instead of the methylase activity of the DNMT1 pro-
tein on the hemi-methylated substrate present in the sample.
Based on the finding that the amount of DNMT1 does not directly
correlate with the activity of this protein present in the sample, it
is likely that other posttranslational factorsmust influence the ac-
tivity of DNMT1 (Roundtree et al., 2000; Smallwood et al., 2007).
If one considers the various sources of changes in protein
activity, it is understandable that the electrochemical assay,
which directly measures the methyltransferase activity on a
hemi-methylated target, would yield the clearest diagnostic for
DNMT1 as a source of epigenetic change within a given tissue.
Measurement of protein activity is closest in time and space to
the epigenetic changes responsible for cancerous transforma-
tion, certainly as compared with the measurement of mRNA for
the methyltransferase, which reflects effects on transcription
and even measurements of the abundance of protein, reflecting
the status of DNMT1 following translation. What is key for
cancerous transformation is the activity itself, turning on and
off given genes as a result of methylation. The fact that onlytd All rights reserved
Figure 5. DNMT1 Expression and DNMT1
Protein Quantification
The fold excess DNMT1 expression is determined
with RT-qPCR (left), which shows just as many
samples with overexpression of DNMT1 in the
tumor (fold excess >1) as with equivalent expres-
sion (fold excess 1) and underexpression (fold
excess <1). The RT-qPCR expression data for
DNMT1 expression in the tumor tissue are
normalized to that of the normal adjacent tissue.
The error represents the SE across four replicates.
The DNMT1 protein content (right), determined by
western blot, follows the same trend as the fold
excess DNMT1 expression; overexpression in the
tumor sample correlates to more protein in that
sample compared with the normal adjacent tissue.
The same trends are observed for those samples
with equivalent expression and underexpression.
For DNMT1 protein quantification, the measured intensity of the DNMT1 band is normalized to the Lamin A loading control, and subsequently, data for the tumor
tissue are normalized to the normal adjacent tissue. Error bars represent SE across four sets of western blots. Sample bands used for quantification are shown in
Figure S3. Each of the letters represents one of the tumor and healthy adjacent tissue sets, and the bar denoted ‘‘Cells’’ represents the result from the comparison
between HCT116 colorectal carcinoma and healthy CCD-18Co cultured cells.some of the tumorigenic changes in a sample depend on the
amount of DNMT1, measured by western blot or expression
levels, underscores that point; tumorigenic changes are also
seen to depend upon enzymatic hyperactivity of a given methyl-
transferase. In developing assays for epigenetic changes as a
source of tumorigenic change, this point needs to be kept in
mind. In sum, using our electrochemical data it is clear that
tumorigenesis does indeed correlate with DNMT1 hyperactivity,
and hence the electrochemistry provides a useful early and sen-
sitive diagnostic for cancerous transformation.
SIGNIFICANCE
We have developed an electrochemical platform based on
DNA charge transport for themeasurement of DNMT1 activ-
ity from crude lysate samples. Using this platform to analyze
ten colorectal carcinoma samples, as well as cultured colo-
rectal carcinoma cells, we find a direct correlation between
hyperactivity of DNMT1 and tumorous tissue. Significant
hyperactivity of the protein is found in the majority of
samples. This hyperactivity does not correlate with either
overexpression or total amount of DNMT1within the sample.
Instead, significant enzyme hyperactivity is frequently evi-
dent. Furthermore, DNMT1 hyperactivity as an indicator of
cancerous transformation, measured electrochemically, is
not clearly observed with the current standard techniques
of DNMT1 analysis, including tritium labeling, RT-qPCR,
and western blotting. Thus our electrochemical platform
has the potential to provide a sensitive method of detecting
DNMT1-related cancerous transformations, with greater
reliability than current DNMT1 analysis techniques.
EXPERIMENTAL PROCEDURES
RT-qPCR
Total RNA was extracted from 30 mg of tissue and 3 million cultured cells of
each cell type. Tissue samples were received snap-frozenwith no further treat-
ment. Tissue samples were homogenized in a total RNA extraction lysis buffer
from a RNEasy kit (Qiagen). The total RNA extracted using this kit was eluted
into a 300 ml of RNAse-free water.Chemistry & Biology 22,Following RNA isolation, RT-PCR was performed to make a complete cDNA
library using a Transcription First Strand cDNA Synthesis kit (Roche) and stan-
dard RT-PCR thermocycler conditions (C1000 Touch Thermal Cycler, Bio-
Rad). Total cDNA concentrations were determined by nanodrop. For these
samples, 250 ng/ml of total DNA was used.
Three DNMT1 primer sets were evaluated for consistency and reproduc-
ibility. b-Actin expression was evaluated to normalize the DNMT1 results
with primers from RealTime Primers; GAPDH was also evaluated as a
housekeeping gene but was observed to be extremely variable. DNMT1
primers were obtained from RealTime Primers, qSTAR, and Genocopeiea.
DNMT1 primers from RealTime Primers were found to have the most
consistent results over multiple trials, and were therefore used for evalua-
tion of all tissue samples. Each sample was run in quadruplicate for RT-
qPCR measurements. RT-qPCR was performed on a CFX 96 Real-Time
PCR Detection System (Bio-Rad). RT-qPCR results were calculated using
a relative quantification method, using the DDCt method to determine fold
excess of the mRNA between the adjacent normal and tumor tissue. Error
was propagated throughout the experiment for four samples of each primer
and sample set.
Cell and Tumor Preparation for 3H Assay and Electrochemistry
100 mg of each tissue sample was prepared as a crude cell lysate. Tissue
samples were homogenized before nuclear isolation using a 3-ml homoge-
nizer with 100 strokes of the pestle. Cultured cells were harvested upon
confluence (approximately 7 million cells) and taken directly to rinsing.
Both tissue and cultured cells were rinsed with 1 ml of phosphate buffer
(5 mM phosphate, 50 mM NaCl [pH 7.0]) and centrifuged. The tissue and
cells were then prepared with a commercial NE-PER Nuclear and Cyto-
plasmic Extraction kit (Thermo Scientific). Following nuclear lysis, the lysate
was buffer exchanged with a 10-kDa spin column into DNMT1 reaction buffer
(50 mM Tris-HCl, 1 mM EDTA, 5% glycerol [pH 7.8]), flash-frozen, and stored
at 80C.
Once the nuclear lysate was aliquoted and frozen, total protein concentra-
tions were determined using a bicinchoninic acid assay kit (Pierce) for protein
concentration. Concentrations of lysate were found to range from 1,000 to
6,000 mg/ml of protein. For all assays, tissue samples were normalized to total
protein concentration.
3H Assay
Tritium assays were performed using the protocol previously established in
our laboratory (Muren and Barton, 2013). The DNA used as a substrate for
electrochemical measurements, with sequences provided in the Supple-
mental Information, including the hexynyl terminal modification, was used
in this radioactive methyltransferase activity assay. 0.5 mCi [3H]SAM with
20 mM DNA, 100 mg/ml of BSA, and lysate (final concentration of 500 mg/ml938–945, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 943
Figure 6. Direct Comparison between
DNMT1 Activity Measured Electrochemi-
cally and DNMT1 Expression
The two bar graphs directly compare the fold
excess protein activity (blue) measured electro-
chemically and the fold excess gene expression
(red). The error bars for the protein activity repre-
sent standard error for three trials, and for the gene
activity, the error bars represent standard error for
four trials. There is no correlation evident between
the amount of expression of DNMT1 and the
eventual activity of DNMT1 found in the tissue.
Each of the letters represents one of the tumor
and healthy adjacent tissue sets, and the bar de-
noted ‘‘Cells’’ represents the result from the com-
parison between HCT116 colorectal carcinoma
and healthy CCD-18Co cultured cells.total protein) were combined to a total volume of 20 ml in DNMT1 reaction
buffer (50 mM Tris-HCl, 1 mM EDTA, 5% glycerol [pH 7.8]). Samples with pu-
rifiedDNMT1 (BPSBiosciences) were used as a positive standard, alongwith a
negative standard with no methyltransferase. Reactions were incubated for
2 hr at 37C, followed by quenching with 30 ml of 10% trichloroacetic acid in
water. The solutions were then spotted onto DE81 filter paper (Whatman)
and air-dried for 15 min. Each filter paper was then washed by individually
soaking it in 10 ml of 50 mM Na2HPO4 for 15 min, followed by rinsing with
50 mM Na2HPO4 and 95% ethanol. Filter papers were heated to 37
C to dry
for 15 min before liquid scintillation counting. Fold excess for radioactive mea-
surements of a given tumor set was determined by taking the ratio of the
counts for the tumor lysate on the hemi-methylated substrate to the tumor
lysate on the unmethylated substrate divided by that same ratio for the normal
tissue lysate.
Electrochemistry
Electrochemistry was performed on a bipotentiostat (CHInstruments 760E)
with two working electrodes, a platinum counter electrode and an AgCl/Ag
reference electrode. Constant potential amperometry electrochemical mea-
surements were recorded for 90 s with an applied potential of 320 mV to the
secondary electrode and 400 mV to the primary electrode. Constant poten-
tial amperometry measurements were performed in Tris buffer (10 mM Tris,
100 mM KCl, 2.5 mM MgCl2, 1 mM CaCl2 [pH 7.6]) with 4 mM methylene
blue and 300 mM potassium ferricyanide. Scans were taken individually at
each of the 15 secondary pin-electrode sets. The percent signal remaining
data are reported as compared with pure DNMT1, with variation in the data
representing the SE across three measurements of three electrodes, all at a
given condition.
To incubate electrodes with desired proteins, a 1.25-mm deep Teflon
spacer was attached to the primary electrode surface with clips to form
an isolated 4-ml volume well around each electrode. In general, three elec-
trodes on the device were incubated with 65 nM DNMT1 and 160 mM SAM,
and 100 mg/ml BSA as a positive control. For electrodes incubated with
lysate, the lysate was diluted to a final concentration of 200 mg/ml and
directly combined with SAM to a final SAM concentration of 160 mM with
50 mg/ml BSA. Three electrodes modified with hemi-methylated DNA
were treated with tumor lysate and three with adjacent normal tissue
lysate. Similarly, three electrodes modified with unmethylated DNA were
incubated with tumor lysate and three with normal tissue lysate. Each elec-
trode had 4 ml of the desired solution added to the well. The platform was
incubated at 37C for 1.5 hr in a humidified container. The DNA monolayers
were then treated with 1 mM protease solution in phosphate buffer (5 mM
phosphate, 50 mM NaCl [pH 7.0]) for 1 hr, followed by thorough rinsing
with phosphate buffer (5 mM phosphate, 50 mM NaCl [pH 7.0]) and scan-
ning by constant potential amperometry. The restriction enzyme BssHII
was then added at a concentration of 1,500 units/ml for 1.5 hr at 37C.
BssHII was prepared by buffer exchange into DNMT1 reaction buffer
(50 mM Tris-HCl, 1 mM EDTA, 5% glycerol [pH 7.8]) using a size-exclusion
column (10 kDa, Amicon). The electrodes were again rinsed with phosphate944 Chemistry & Biology 22, 938–945, July 23, 2015 ª2015 Elsevier Lbuffer and scanned. Results from three trials per tumor sample were aggre-
gated and averaged. Fold excess for electrochemical measurements of a
given tumor set was determined by taking the ratio of the percent signal
remaining for the tumor lysate on the hemi-methylated substrate to the tu-
mor lysate on the unmethylated substrate divided by that same ratio for the
normal tissue lysate.
Western Blot Analysis of Lysate for DNMT1
The relative amount of DNMT1 protein in each tumor set was established by
western blot. Samples were diluted to a final loading of 60 mg of protein per
lane with DNMT1 reaction buffer (50 mM Tris-HCl, 1 mM EDTA, 5% glycerol
[pH 7.8]) and Laemmli reagent with b-mercaptoethanol. Samples were probe
sonicated for 10 s at 20% power, followed by boiling at 90C for 5 min. Sam-
ples were loaded onto 4%–12% polyacrylamide gels in MOPS SDS buffer
(50 mM 3-(N-morpholino)propanesulfonic acid [MOPS], 50 mM Tris base,
0.1% SDS, 1 mM EDTA [pH 7.7]) and run at 175 mV for 2.5 hr at 4C. Gels
were subsequently transferred to membranes with a dry transfer procedure
for 1.5 hr. Membranes were blocked with 5% milk in TBST (20 mM Tris
base, 150 mM NaCl, 0.1% Tween 20 [pH 7.6]) at room temperature for 1 hr,
followed by overnight incubation with a 1 antibody in 5% milk in TBST
(1:1,000 for DNMT1 [R & D] and 1:1,000 for Lamin A [Santa Cruz]). The mem-
branes were then rinsed with TBST buffer. Lamin A membranes were incu-
bated with goat anti-rabbit 2 antibody (Abcam) (1:5,000 in 5% milk with
0.02% SDS in TBST) or Donkey Anti Sheep for DNMT1 (Santa Cruz)
(1:5,000) for 1 hr and then rinsed with TBST. Membranes were scanned on a
Li-Cor Odyssey CLx infrared gel scanner, and bands were quantified using Im-
age Studio software.
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